The relationship of human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS) with the incident of cardiovascular disease: is the existing evidence consistent?
Article Sidebar
Main Article Content
Page: 544-552
Abstract
Human Immunodeficiency Virus (HIV) and Acquired Immune Deficiency Syndrome (AIDS) pose ongoing global health challenges. This literature review evaluates the relationship between HIV infection and increased cardiovascular diseases, outlining findings from sixteen observational studies. Key findings involve an elevated risk of hypertension, coronary artery disease, sudden cardiac death, and cardiovascular risk factors among HIV patients. Additionally, antiretroviral therapy (ART) side effects are highlighted, including specific impacts of certain drugs. The gender of HIV/AIDS patients also plays a role in cardiovascular risk profiles. The study details the pathophysiological mechanisms, such as immune activation and inflammation, involved in the heightened cardiovascular risk in individuals with HIV/AIDS. This study underscores the importance of a comprehensive understanding of cardiovascular health impacts on the HIV/AIDS population to guide informed therapeutic choices for preventing cardiovascular status deterioration.
Downloads
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
References
Deeks SG, Overbaugh J, Phillips A, Buchbinder S. HIV infection. Nat Rev Dis Primer 2015;1:15035. https://doi.org/10.1038/nrdp.2015.35. DOI: https://doi.org/10.1038/nrdp.2015.35
Govender RD, Hashim MJ, Khan MA, Mustafa H, Khan G. Global Epidemiology of HIV/AIDS: A Resurgence in North America and Europe. J Epidemiol Glob Health 2021;11:296–301. https://doi.org/10.2991/jegh.k.210621.001. DOI: https://doi.org/10.2991/jegh.k.210621.001
World Health Organization. HIV and AIDS 2023. https://www.who.int/news-room/fact-sheets/detail/hiv-aids (accessed October 1, 2023).
Umar TP. Intravaginal ring as human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS) prevention. Br Stud Dr J 2022;6:59–69. https://doi.org/10.18573/bsdj.221. DOI: https://doi.org/10.18573/bsdj.221
Rather ZA, Chowta MN, Raju GJKP, Mubeen F. Evaluation of the adverse reactions of antiretroviral drug regimens in a tertiary care hospital. Indian J Pharmacol 2013;45:145–8. https://doi.org/10.4103/0253-7613.108294. DOI: https://doi.org/10.4103/0253-7613.108294
Triant VA. Cardiovascular Disease and HIV Infection. Curr HIV/AIDS Rep 2013;10:199–206. https://doi.org/10.1007/s11904-013-0168-6. DOI: https://doi.org/10.1007/s11904-013-0168-6
Desai M, Joyce V, Bendavid E, Olshen RA, Hlatky M, Chow A, et al. Risk of cardiovascular events associated with current exposure to HIV antiretroviral therapies in a US veteran population. Clin Infect Dis Off Publ Infect Dis Soc Am 2015;61:445–52. https://doi.org/10.1093/cid/civ316. DOI: https://doi.org/10.1093/cid/civ316
Alvi RM, Neilan AM, Tariq N. Protease Inhibitors and Cardiovascular Outcomes in Patients With HIV and Heart Failure. J Am Coll Cardiol 2018;72:518–30. https://doi.org/10.1016/j.jacc.2018.04.083. DOI: https://doi.org/10.1016/j.jacc.2018.04.083
Alvi RM, Neilan AM, Tariq N. The Risk for Sudden Cardiac Death Among Patients Living With Heart Failure and Human Immunodeficiency Virus. JACC Heart Fail 2019;7:759–67. https://doi.org/10.1016/j.jchf.2019.04.025. DOI: https://doi.org/10.1016/j.jchf.2019.04.025
Batavia AS, Severe P, Lee MH, Apollon A, Zhu YS, Dupnik KM, et al. Blood pressure and mortality in a prospective cohort of HIV-infected adults in Port-au-Prince, Haiti. J Hypertens 2018;36:1533. https://doi.org/10.1097/HJH.0000000000001723. DOI: https://doi.org/10.1097/HJH.0000000000001723
Beckman JA, Duncan MS, Alcorn CW, So-Armah K, Butt AA, Goetz MB, et al. Association of Human Immunodeficiency Virus Infection and Risk of Peripheral Artery Disease. Circulation 2018;138:255–65. https://doi.org/10.1161/CIRCULATIONAHA.117.032647. DOI: https://doi.org/10.1161/CIRCULATIONAHA.117.032647
Castillo-Mancilla JR, Cavassini M, Schneider MP, Furrer H, Calmy A, Battegay M, et al. Association of Incomplete Adherence to Antiretroviral Therapy With Cardiovascular Events and Mortality in Virologically Suppressed Persons With HIV: The Swiss HIV Cohort Study. Open Forum Infect Dis 2021;8:ofab032. https://doi.org/10.1093/ofid/ofab032. DOI: https://doi.org/10.1093/ofid/ofab032
Costagliola D, Potard V, Lang S, de Castro N, Cotte L, Duval X, et al. Is the Risk of Myocardial Infarction in People With Human Immunodeficiency Virus (HIV) Associated With Atazanavir or Darunavir? A Nested Case-Control Study Within the French Hospital Database on HIV. J Infect Dis 2020;221:516–22. https://doi.org/10.1093/infdis/jiz481. DOI: https://doi.org/10.1093/infdis/jiz481
Foldyna B, Fourman LT, Lu MT, Mueller ME, Szilveszter B, Neilan TG, et al. Sex Differences in Subclinical Coronary Atherosclerotic Plaque Among Individuals with HIV on Antiretroviral Therapy. J Acquir Immune Defic Syndr 1999 2018;78:421–8. https://doi.org/10.1097/QAI.0000000000001686. DOI: https://doi.org/10.1097/QAI.0000000000001686
Fourie CMT, Botha-Le Roux S, Smith W, Schutte AE, Breet Y, Mels CMC, et al. Vascular function and cardiovascular risk in a HIV infected and HIV free cohort of African ancestry: baseline profile, rationale and methods of the longitudinal EndoAfrica-NWU study. BMC Infect Dis 2020;20:473. https://doi.org/10.1186/s12879-020-05173-6. DOI: https://doi.org/10.1186/s12879-020-05173-6
Knudsen A, Thorsteinsson K, Christensen TE, Hasbak P, Ripa RS, Panum I, et al. Cardiac Microvascular Dysfunction in Women Living With HIV Is Associated With Cytomegalovirus Immunoglobulin G. Open Forum Infect Dis 2018;5:ofy205. https://doi.org/10.1093/ofid/ofy205. DOI: https://doi.org/10.1093/ofid/ofy205
Kolossváry M, Celentano D, Gerstenblith G, Bluemke DA, Mandler RN, Fishman EK, et al. HIV indirectly accelerates coronary artery disease by promoting the effects of risk factors: longitudinal observational study. Sci Rep 2021;11:23110. https://doi.org/10.1038/s41598-021-02556-w. DOI: https://doi.org/10.1038/s41598-021-02556-w
Kovari H, Calmy A, Doco-Lecompte T, Nkoulou R, Marzel A, Weber R, et al. Antiretroviral Drugs Associated With Subclinical Coronary Artery Disease in the Swiss Human Immunodeficiency Virus Cohort Study. Clin Infect Dis Off Publ Infect Dis Soc Am 2020;70:884–9. https://doi.org/10.1093/cid/ciz283. DOI: https://doi.org/10.1093/cid/ciz283
Lai Y-J, Chen Y-Y, Huang H-H, Ko M-C, Chen C-C, Yen Y-F. Incidence of cardiovascular diseases in a nationwide HIV/AIDS patient cohort in Taiwan from 2000 to 2014. Epidemiol Infect 2018;146:2066–71. https://doi.org/10.1017/S0950268818002339. DOI: https://doi.org/10.1017/S0950268818002339
Oliveira R, Shimakura S, Campos D, Hökerberg Y, Victoriano F, Ribeiro S, et al. Effects of antiretroviral treatment and nadir CD4 count in progression to cardiovascular events and related comorbidities in a HIV Brazilian cohort: a multi-stage approach. AIDS Care 2018;30:551–9. https://doi.org/10.1080/09540121.2017.1391984. DOI: https://doi.org/10.1080/09540121.2017.1391984
Policarpo S, Rodrigues T, Moreira AC, Valadas E. Cardiovascular risk in HIV-infected individuals: A comparison of three risk prediction algorithms. Rev Port Cardiol 2019;38:463–70. https://doi.org/10.1016/j.repc.2019.08.002.
Ryom L, Lundgren JD, El-Sadr W, Reiss P, Kirk O, Law M, et al. Cardiovascular disease and use of contemporary protease inhibitors: the D:A:D international prospective multicohort study. Lancet HIV 2018;5:e291–300. https://doi.org/10.1016/S2352-3018(18)30043-2. DOI: https://doi.org/10.1016/S2352-3018(18)30043-2
Vos AG, Barth RE, Klipstein‐Grobusch K, Tempelman HA, Devillé WLJ, Dodd C, et al. Cardiovascular Disease Burden in Rural Africa: Does HIV and Antiretroviral Treatment Play a Role? J Am Heart Assoc Cardiovasc Cerebrovasc Dis 2020;9:e013466. https://doi.org/10.1161/JAHA.119.013466. DOI: https://doi.org/10.1161/JAHA.119.013466
Anne-Lise P, Chang C-CH, So-Armah KA, Butt AA, Leaf DA, Budoff M, et al. Human immunodeficiency virus infection, cardiovascular risk factor profile and risk for acute myocardial infarction. J Acquir Immune Defic Syndr 1999 2015;68:209–16. https://doi.org/10.1097/QAI.0000000000000419. DOI: https://doi.org/10.1097/QAI.0000000000000419
Gandhi RT, Bedimo R, Hoy JF, Landovitz RJ, Smith DM, Eaton EF, et al. Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2022 Recommendations of the International Antiviral Society–USA Panel. JAMA 2023;329:63–84. https://doi.org/10.1001/jama.2022.22246. DOI: https://doi.org/10.1001/jama.2022.22246
Reyskens KMSE, Essop MF. HIV protease inhibitors and onset of cardiovascular diseases: A central role for oxidative stress and dysregulation of the ubiquitin–proteasome system. Biochim Biophys Acta BBA - Mol Basis Dis 2014;1842:256–68. https://doi.org/10.1016/j.bbadis.2013.11.019. DOI: https://doi.org/10.1016/j.bbadis.2013.11.019
Lv Z, Chu Y, Wang Y. HIV protease inhibitors: a review of molecular selectivity and toxicity. HIV/AIDS 2015;7:95–104. https://doi.org/10.2147/HIV.S79956. DOI: https://doi.org/10.2147/HIV.S79956
Policarpo S, Rodrigues T, Moreira AC, Valadas E. Cardiovascular risk in HIV-infected individuals: A comparison of three risk prediction algorithms. Rev Port Cardiol 2019;38:463–70. https://doi.org/10.1016/j.repc.2019.08.002. DOI: https://doi.org/10.1016/j.repc.2019.08.002
Ziadi MC. Myocardial flow reserve (MFR) with positron emission tomography (PET)/computed tomography (CT): clinical impact in diagnosis and prognosis. Cardiovasc Diagn Ther 2017;7:206–18. https://doi.org/10.21037/cdt.2017.04.10. DOI: https://doi.org/10.21037/cdt.2017.04.10
So-Armah K, Benjamin LA, Bloomfield GS, Feinstein MJ, Hsue P, Njuguna B, et al. HIV and cardiovascular disease. Lancet HIV 2020;7:e279–93. https://doi.org/10.1016/S2352-3018(20)30036-9. DOI: https://doi.org/10.1016/S2352-3018(20)30036-9
Neuhaus J, Jacobs, Jr DR, Baker JV, Calmy A, Duprez D, La Rosa A, et al. Markers of Inflammation, Coagulation, and Renal Function Are Elevated in Adults with HIV Infection. J Infect Dis 2010;201:1788–95. https://doi.org/10.1086/652749. DOI: https://doi.org/10.1086/652749
Barbaro G, Di Lorenzo G, Grisorio B, Barbarini G, THE GRUPPO ITALIANO PER LO STUDIO CARDIOLOGICO DEI PAZIENTI AFFETTI DA AIDS INVESTIGATORS4. Cardiac Involvement in the Acquired Immunodeficiency Syndrome: A Multicenter Clinical-Pathological Study. AIDS Res Hum Retroviruses 1998;14:1071–7. https://doi.org/10.1089/aid.1998.14.1071. DOI: https://doi.org/10.1089/aid.1998.14.1071
Abelman RA, Mugo BM, Zanni MV. Conceptualizing the Risks of Coronary Heart Disease and Heart Failure Among People Aging with HIV: Sex-Specific Considerations. Curr Treat Options Cardiovasc Med 2019;21:41. https://doi.org/10.1007/s11936-019-0744-1. DOI: https://doi.org/10.1007/s11936-019-0744-1
Grody WW, Cheng L, Lewis W. Infection of the heart by the human immunodeficiency virus. J Am Coll Cardiol 1990;66:203–6. https://doi.org/10.1016/0002-9149(90)90589-S. DOI: https://doi.org/10.1016/0002-9149(90)90589-S
Brenchley JM, Price DA, Schacker TW, Asher TE, Silvestri G, Rao S, et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med 2006;12:1365–71. https://doi.org/10.1038/nm1511. DOI: https://doi.org/10.1038/nm1511
Riddler SA. Impact of HIV Infection and HAART on Serum Lipids in Men. JAMA 2003;289:2978. https://doi.org/10.1001/jama.289.22.2978. DOI: https://doi.org/10.1001/jama.289.22.2978
Veenstra M, León-Rivera R, Li M, Gama L, Clements JE, Berman JW. Mechanisms of CNS Viral Seeding by HIV + CD14 + CD16 + Monocytes: Establishment and Reseeding of Viral Reservoirs Contributing to HIV-Associated Neurocognitive Disorders. mBio 2017;8:e01280-17. https://doi.org/10.1128/mBio.01280-17. DOI: https://doi.org/10.1128/mBio.01280-17
Benjamin LA, Allain TJ, Mzinganjira H, Connor MD, Smith C, Lucas S, et al. The Role of Human Immunodeficiency Virus–Associated Vasculopathy in the Etiology of Stroke. J Infect Dis 2017;216:545–53. https://doi.org/10.1093/infdis/jix340. DOI: https://doi.org/10.1093/infdis/jix340